QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.01
(-5.1%)
SEK 0.01
(-5.1%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 20.61 Million SEK | 32.79% |
| 2022 | 15.52 Million SEK | -12.79% |
| 2021 | 17.79 Million SEK | 13.01% |
| 2020 | 15.75 Million SEK | -9.04% |
| 2019 | 17.31 Million SEK | 185.96% |
| 2018 | 6.05 Million SEK | 10.09% |
| 2017 | 5.5 Million SEK | 0.0% |
| 2016 | - SEK | -100.0% |
| 2015 | 218 Thousand SEK | -65.62% |
| 2014 | 634 Thousand SEK | 13.21% |
| 2013 | 560 Thousand SEK | -24.02% |
| 2012 | 737 Thousand SEK | -31.06% |
| 2011 | 1.06 Million SEK | -1.2% |
| 2010 | 1.08 Million SEK | -25.17% |
| 2009 | 1.44 Million SEK | -14.94% |
| 2008 | 1.7 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 3.32 Million SEK | 0.0% |
| 2024 Q1 | 3.32 Million SEK | -83.86% |
| 2023 Q1 | 11.67 Million SEK | -24.79% |
| 2023 Q2 | 11.67 Million SEK | 0.0% |
| 2023 Q3 | 20.61 Million SEK | 76.55% |
| 2023 Q4 | 20.61 Million SEK | 0.0% |
| 2023 FY | 20.61 Million SEK | 32.79% |
| 2022 Q4 | 15.52 Million SEK | 2.45% |
| 2022 FY | 15.52 Million SEK | -12.79% |
| 2022 Q1 | 19.82 Million SEK | 11.39% |
| 2022 Q2 | 15.15 Million SEK | -23.58% |
| 2022 Q3 | 15.15 Million SEK | 0.0% |
| 2021 Q4 | 17.79 Million SEK | 3.91% |
| 2021 Q3 | 17.13 Million SEK | 506.59% |
| 2021 Q2 | 2.82 Million SEK | -74.22% |
| 2021 Q1 | 10.95 Million SEK | -30.45% |
| 2021 FY | 17.79 Million SEK | 13.01% |
| 2020 Q4 | 15.75 Million SEK | 38.85% |
| 2020 Q2 | 23.4 Million SEK | 74.59% |
| 2020 Q3 | 11.34 Million SEK | -51.54% |
| 2020 Q1 | 13.4 Million SEK | -22.57% |
| 2020 FY | 15.75 Million SEK | -9.04% |
| 2019 Q2 | 2.14 Million SEK | -8.32% |
| 2019 Q4 | 17.31 Million SEK | 24.09% |
| 2019 FY | 17.31 Million SEK | 185.96% |
| 2019 Q1 | 2.34 Million SEK | -61.3% |
| 2019 Q3 | 13.95 Million SEK | 549.63% |
| 2018 Q3 | 3.18 Million SEK | 37.62% |
| 2018 FY | 6.05 Million SEK | 10.09% |
| 2018 Q4 | 6.05 Million SEK | 90.05% |
| 2018 Q2 | 2.31 Million SEK | -5.66% |
| 2018 Q1 | 2.45 Million SEK | -55.38% |
| 2017 FY | 5.5 Million SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | 5.5 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | - SEK | -100.0% |
| 2016 Q2 | 224 Thousand SEK | 0.0% |
| 2016 Q3 | - SEK | -100.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 Q4 | 218 Thousand SEK | 0.0% |
| 2015 FY | 218 Thousand SEK | -65.62% |
| 2015 Q2 | 599 Thousand SEK | 0.0% |
| 2014 FY | 634 Thousand SEK | 13.21% |
| 2014 Q4 | 634 Thousand SEK | 0.0% |
| 2014 Q2 | 576 Thousand SEK | 0.0% |
| 2013 FY | 560 Thousand SEK | -24.02% |
| 2013 Q2 | 749 Thousand SEK | 0.0% |
| 2013 Q4 | 560 Thousand SEK | 0.0% |
| 2012 FY | 737 Thousand SEK | -31.06% |
| 2012 Q4 | 737 Thousand SEK | 0.0% |
| 2012 Q2 | 887 Thousand SEK | 0.0% |
| 2011 Q2 | 969 Thousand SEK | 0.0% |
| 2011 FY | 1.06 Million SEK | -1.2% |
| 2010 Q2 | 1.32 Million SEK | 0.0% |
| 2010 FY | 1.08 Million SEK | -25.17% |
| 2009 FY | 1.44 Million SEK | -14.94% |
| 2008 FY | 1.7 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | 3 Million SEK | -587.033% |
| Biovica International AB (publ) | 7.82 Million SEK | -163.298% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Cyxone AB (publ) | 858 Thousand SEK | -2302.214% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -1104.617% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | 15.832% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Intervacc AB (publ) | 181 Thousand SEK | -11287.293% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 65.82% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 91.096% |
| Lipum AB (publ) | 1.76 Million SEK | -1070.415% |
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -28.042% |
| Ziccum AB (publ) | 857 Thousand SEK | -2305.018% |
| BioArctic AB (publ) | 4.97 Million SEK | -313.959% |
| Genovis AB (publ.) | 79.32 Million SEK | 74.015% |
| Camurus AB (publ) | 24.5 Million SEK | 15.897% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 25.23% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -312.22% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 44.004% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 71.137% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -4761.085% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -571.368% |
| Amniotics AB (publ) | 2.58 Million SEK | -698.876% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -1961.1% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 97.895% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 97.622% |
| Biosergen AB | - SEK | -Infinity% |
| Corline Biomedical AB | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -2994.745% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 81.021% |
| BioInvent International AB (publ) | 23.24 Million SEK | 11.328% |
| SynAct Pharma AB | 637 Thousand SEK | -3135.636% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -2324.824% |
| Alzinova AB (publ) | 800 Thousand SEK | -2476.375% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -1842.601% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 80.645% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -2566.089% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 77.286% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 32.802% |